samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Perfect Gx Elite vials presented by Gerresheimer at CPhI Worldwide

Gerresheimer AG

They result from a comprehensive optimization measures in the conversion process

Düsseldorf/Frankfurt, October 24, 2017. The Gx Elite vials have set new standards for type 1 borosilicate glass vials. They are the result of comprehensive optimization measures in the conversion process, which have focused on designing out the risk to create product flaws during production including the removal of all glass-to-glass contact beginning with the tubing material all the way through final packaging. The chemical composition of the borosilicate glass is still the same. Gerresheimer will be showcasing Gx Elite vials at booth D02 in Hall 4.2 at CPhI Worldwide in Frankfurt (Germany) from October 24 to 26, 2017.

The best in its class
"Our Gx Elite vials are setting new standards when it comes to quality," says Jens Heymann, Senior Vice President Europe & Asia Tubular Glass at Gerresheimer, underlining the major difference that avoiding glass-to-glass contact in the production process can have on vial quality. The highly shatter-resistant vials are extremely durable and free of cosmetic defects. They also boast an incredibly robust structure, while their resistance to delamination protects the drug inside. Simple handling and a range of packaging options ensure that Gx Elite vials can be supplied for end-to-end use on various filling lines. For customers, this means lower costs and higher quality.

Intelligent defect recognition
All of Gerresheimer’s tubular glass plants that produce vials work with standardized monitoring, inspection, and packaging technologies, which essentially comprise the Gx G3 and Gx RHOC systems. The inspection systems, for one, are developed in house and form part of a close-knit testing system that ensures the highest precision and quality assurance in line with the latest standards. Complete with five HD cameras, the Gx G3 inspection system makes sure that cosmetic defects are identified reliably, for instance. The intelligent software detects and classifies the defects in a few fractions of a second, while the Gx RHOC system ensures dimensional quality with three HD matrix cameras on each side and a hypercentric ID camera.

Injection vials set the benchmark for primary packaging for parenteral drugs. Gerresheimer’s vials come in all sizes and comply with the relevant international standards and pharmacopoeias (EU, USP, JP). The company’s range includes solutions for bioengineered drugs and other specialist pharmaceuticals.

More info

Tubular glass injection vials

About Gerresheimer

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With our plants in Europe, North America, South America, and Asia, we generate revenues of approximately EUR 1.4 billion. The company’s comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Press Contact
Jens Kürten
Group Senior Director Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241
E-mail j.kuerten@gerresheimer.com

Marion Stolzenwald
Senior Manager Corporate Communication
Phone +49 211 6181-246
Fax +49 211 6181-241
E-mail m.stolzenwald@gerresheimer.com
phone +49-(0)211/61 81-00
email info@gerresheimer.com
web www.gerresheimer.com
email Klaus-Bungert-Str. 4, 40468 Duesseldorf, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Horizon Discovery Licenses Biomanufacturing Cell Lines to Centre for Process Innovation (CPI) and National Institute for Bioprocessing Research and Training (NIBRT)


More info >>


White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

Industry Events

ASPIRE: International EDGE Conference

28 February - 1 March 2018, The Vox Conference Centre, Birmingham

The ASPIRE international conference is taking place on the 28th February and 1st March 2018 at the Vox Conference Centre in Birmingham. The conference brings together members of the research community including research professionals from the NHS, Clinical Trial Networks and international organisations. The ASPIRE conference will allow delegates to share knowledge and best practise with the focus on enhancing the efficiency and productivity of clinical research across the UK and beyond.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement